Rare Rheumatology News

Advertisement

Spotlight On

Giant cell arteritis

Giant cell arteritis is a chronic disease associated with vision loss, headaches, polymyalgia rheumatica, jaw and limb claudication, and aortic aneurysms

Prevalence

1-5/10,000

33,100-165,500

US Estimated

51,350-256,750

Europe Estimated

Age of Onset

ICD-10

M31.6

Inheritance

Autosomal dominant

Autosomal recessive

Mitochondrial/Multigenic

X-linked dominant

X-linked recessive

5 Facts you should know

FACT

1

GCA affects only older adults, with a peak incidence between ages 70 and 79

 

FACT

2

The most common symptoms of giant cell arteritis are head pain and tenderness — often severe — that usually affects both temples

FACT

3

Most of the clinical features of GCA result from vascular inflammation of the small extracranial branches of the carotid arteries

 

FACT

4

One of the most concerning potential complications of GCA is that of sight loss, which serves as the rationale for prompt initiation of glucocorticoids as soon as the diagnosis is suspected

 

FACT

5

GCA can overlap with polymyalgia rheumatica (PMR) - at some point, 5 – 15% of patients with PMR will have a diagnosis of GCA

 

Giant cell arteritis is also known as...

Giant cell arteritis is also known as:

  • GCA
  • Temporal arteritis
  • Cranial arteritis
     
     

What’s your Rare IQ?

Which or the following is the most common vasculitis?

Common signs & symptoms

Anorexia

Cerebral ischemia

Fatigue

Fever

Headache

Impaired mastication

Joint stiffness

Vasculitis

Current treatments

Giant cell arteritis (GCA) is typically treated with high doses of corticosteroids to reduce the inflammation in the arteries. Corticosteroids should be started promptly (perhaps even before the diagnosis is confirmed with a biopsy). If not treated, GCA may cause permanent vision loss or a stroke. The symptoms of GCA usually quickly disappear with treatment, but high doses of corticosteroids are typically maintained for 1 month. It is known that the treatment is working when the symptoms are gone and the sedimentation rate, also known as sed rate (a blood test that measures the level of inflammatory activity), is normal. The corticosteroid dose may gradually be reduced.[1] Other medicines may help to reduce the doses of corticosteroids.
The U.S. Food and Drug Administration (FDA) approved the use of under the skin injection (subcutaneous) of tocilizumab (Brand name: Actemra) to treat adults with giant cell arteritis.[10] Remember that only your doctor can prescribe a medication, so please talk to your doctor to find out if this medication may be right for you.

 

Top Clinical Trials

Top Treatments in Research